ARTICLE | Clinical News
Cenderitide: Phase II started
March 9, 2015 7:00 AM UTC
Capricor began an open-label, dose-escalation, U.S. Phase II trial to evaluate 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous infusion via the Insulet Drug Delivery System for up ...